Wai Yuen Tong Medicine Holdings (0897) Fair Value & Analysis
Healthcare · HK · Market cap HK$318M
Fair value as of: Aug 15, 2026
From 19 valuation models · updated yesterday
Share price −15.2% over the past month.
A solid business, but screening 71% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$0.1000). The favourable scenario is already priced in.
- Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 15, 2026.
How to read this chart
60‑month range HK$0.1860 – HK$0.4750 · fair‑value band HK$0.0600 – HK$0.1000 · the HK$0.2800 price screens above the HK$0.0800 fair value. Dashed = 300-day average. As of Aug 15, 2026.
Analysis
Wai Yuen Tong Medicine Holdings (0897) currently trades at HK$0.2800, while our model-based Fair Value estimate is HK$0.0800, implying the stock looks roughly 71.4% overvalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Wai Yuen Tong Medicine Holdings generated revenue of HK$721M at a net margin of -1.9%. Revenue declined 6.9% year over year. It earns a return on equity of -1.2%. Net debt stands at HK$146M. Fundamentals as of Aug 15, 2026
Our scenario range runs from HK$0.0600 (bear case) to HK$0.1000 (bull case); at HK$0.2800, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 45% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -71%, 0897 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 19 models by family
Widest divergence: Asset-Based (HK$0.7100) versus Earnings-Based (HK$0.0300). Highest evidence: Growth DCF (80).
Notify me when 0897 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 57 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Wai Yuen Tong Medicine Holdings Limited, an investment holding company, engages in production and sale of Chinese and western pharmaceuticals and health food products in Mainland China and Hong Kong.
Full company description
Wai Yuen Tong Medicine Holdings Limited, an investment holding company, engages in production and sale of Chinese and western pharmaceuticals and health food products in Mainland China and Hong Kong. The company manufactures, processes, and sells traditional Chinese medicines under the brand Wai Yuen Tong brand and western pharmaceutical and personal care products under the Madame Pearl's and Pearl's brands. It also invests in commercial premises for rental. Wai Yuen Tong Medicine Holdings Limited was founded in 1897 and is headquartered in Kowloon Bay, Hong Kong. The company is a subsidiary of Rich Time Strategy Limited.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Wai Yuen Tong Medicine Holdings reported revenue of HK$683M in FY2026 versus HK$1.4B in FY2022, a compound −16.3%/yr. Reported net income was HK$4.0M in FY2026.
0897 screens 71% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare Wai Yuen Tong Medicine Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Wai Yuen Tong Medicine Holdings (0897) overvalued or undervalued?
What is the fair value of 0897?
What is the quality score of 0897?
What is the revenue of Wai Yuen Tong Medicine Holdings (0897)?
What is the net profit margin of 0897?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Wai Yuen Tong Medicine Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.